JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Raises Target Price to $12
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $9
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $9
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $9
JonesTrading Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $9
Elicio Therapeutics Analyst Ratings
JonesTrading Initiates Elicio Therapeutics(ELTX.US) With Buy Rating, Announces Target Price $9
Elicio Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Elicio Therapeutics Analyst Ratings
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $10
Elicio Therapeutics Analyst Ratings
Elicio Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Elicio Therapeutics (ELTX)
Elicio Therapeutics Analyst Ratings
Elicio Therapeutics Analyst Ratings
Elicio Therapeutics Analyst Ratings
Buy Rating Upheld for Elicio Therapeutics Amid Solid Financial Position and Promising Clinical Results
Elicio Therapeutics Analyst Ratings